Earnings, guidance and new deals put Halozyme Therapeutics in focus

Halozyme Therapeutics (HALO) drew fresh attention after reporting second quarter revenue of US$481 million and net income of US$229.91 million, along with higher full year revenue guidance and new ENHANZE collaboration agreements.

The latest earnings, higher 2026 revenue guidance and accelerated buybacks appear to have supported momentum in Halozyme Therapeutics, with a 30 day share price return of 34.67% and a 1 year total shareholder return of 63.17%.

If Halozyme’s recent rally has you thinking about what else could be moving, this is a good moment to scan the market using our 43 healthcare AI stocks.

After a 63.17% 1 year total return and a share price near US$102, Halozyme Therapeutics now sits at the point where strong reported earnings and buybacks meet valuation discipline. The key question is whether the current numbers still leave enough potential upside to justify the risk.

Most Popular Narrative: 18.1% Overvalued

At a last close of $102.62 versus a narrative fair value of $86.89, the most widely followed view on Halozyme Therapeutics points to a richer price than that framework implies, which puts the spotlight on what is driving those underlying assumptions.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Want to see what kind of revenue trajectory and margin profile that narrative is baking in for Halozyme Therapeutics? The most debated assumption sits in how earnings compound against a lower future P/E multiple and still back into that fair value path.

Result: Fair Value of $86.89 (OVERVALUED)

However, Halozyme Therapeutics still faces key risks, including revenue concentration in a few major partners and ongoing patent challenges that could pressure future royalties and earnings assumptions.

Another view on Halozyme Therapeutics’ valuation

While the narrative fair value for Halozyme Therapeutics sits at US$86.89, the SWS DCF model tells a very different story. On this approach, Halozyme screens as undervalued, with the current US$102.62 share price sitting well below an estimated future cash flow value of US$403.52. That gap raises a simple question: Which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Halozyme Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around Halozyme Therapeutics, this is a good time to move quickly, review the key data and decide where you stand. To see both the potential upsides and the issues investors are worried about in one place, check out the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Halozyme Therapeutics?

If you are weighing what comes next after Halozyme Therapeutics, do not stop at a single stock. Use the screeners below to spot fresh opportunities across the market.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive pricing through our 52 high quality undervalued stocks.
• Strengthen your search for income by focusing on companies with higher yields and staying power using the 8 dividend fortresses.
• Prioritize capital protection by zeroing in on companies that carry lower risk scores via the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.